Printer Friendly

Agenus Presents at Cowen Health Care Conference.

Agenus Inc. (Nasdaq:AGEN), Lexington, Mass., a developer of therapeutic vaccines for cancer and infectious diseases, presented at the 32nd Annual Cowen and Company Health Care Conference.

-- Phase 3: GSK's RTS,S for malaria -- Phase 3: GSK's MAGE-A3 for non-small cell lung cancer -- Phase 3: GSK's MAGE-A3 for melanoma -- Phase 3: GSK's Zoster Herpes for shingles -- Phase 2: Janssen's ACC-001 for Alzheimer's disease

Agenus pipeline programs include:

-- Phase 2: Prophage Series G-100 for newly diagnosed glioma -- Phase 2: Prophage Series G-200 for recurrent glioma -- Phase 2 Ready: HerpV (contains QS-21 Stimulon) for genital herpes

Saponin Platform: QS-21 Stimulon(R)Adjuvant

QS-21 licensees include GlaxoSmithKline, Janssen Alzheimer Immunotherapy, and Integrated Biotherapeutics. Agenus is generally entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch.

Heat Shock Protein Platform: Prophage Series G

The Prophage Series G vaccines (HSPPC-96; vitespen) are being studied in two different settings of glioma: newly diagnosed and recurrent disease. Glioma is the deadliest form of brain cancer with an average survival of six to 14 months.

Heat Shock Protein Platform: Recombinant Series HerpV

HerpV is the most advanced HSV-2 vaccine currently in clinical development for the treatment of genital herpes. Agenus plans to advance HerpV into a Phase 2 study in 2012 that will measure the effect of vaccination on viral shedding in individuals infected with HSV-2. Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into the clinical benefit of a reduction in recurrent outbreaks.

Oncophage(R) Vaccine: Approved in Russia for Kidney Cancer

During the fourth quarter of 2011, Agenus and NewVac LLC (a subsidiary of ChemRar), announced a license, development and manufacturing technology transfer agreement for Agenus' Oncophage (HSPPC-96; vitespen) vaccine. Oncophage is approved in Russia for the treatment of renal cell carcinoma (kidney cancer) in patients at intermediate risk of recurrence. Under the agreement, Agenus has granted NewVac an exclusive license to manufacture, market and sell Oncophage as well as pursue a development program of Oncophage in combination with NewVac's co-adjuvant technology in the Russian Federation and CIS countries. Agenus is entitled to receive a transfer price and/or royalties upon Oncophage product sales, and potential milestone payments.

About Agenus

Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners.

For more information, visit www.agenusbio.com or call 617/818-2985.
COPYRIGHT 2012 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Article Type:Conference news
Date:Mar 31, 2012
Words:430
Previous Article:Rubicon Genomics Selects Velesco to Manufacture TransPLEX[R].
Next Article:Zurex PharmAgra, LLC Launches ECAlogix System.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters